ID: ALA1834559

Max Phase: Preclinical

Molecular Formula: C18H15NO

Molecular Weight: 261.32

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  Cn1cc(C(=O)/C=C/c2ccccc2)c2ccccc21

Standard InChI:  InChI=1S/C18H15NO/c1-19-13-16(15-9-5-6-10-17(15)19)18(20)12-11-14-7-3-2-4-8-14/h2-13H,1H3/b12-11+

Standard InChI Key:  VOOOMMHNKOQVAH-VAWYXSNFSA-N

Associated Targets(Human)

RT-112 346 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 261.32Molecular Weight (Monoisotopic): 261.1154AlogP: 4.07#Rotatable Bonds: 3
Polar Surface Area: 22.00Molecular Species: HBA: 2HBD: 0
#RO5 Violations: 0HBA (Lipinski): 2HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: CX LogP: 4.21CX LogD: 4.21
Aromatic Rings: 3Heavy Atoms: 20QED Weighted: 0.51Np Likeness Score: -0.35

References

1. Martel-Frachet V, Kadri M, Boumendjel A, Ronot X..  (2011)  Structural requirement of arylindolylpropenones as anti-bladder carcinoma cells agents.,  19  (20): [PMID:21908193] [10.1016/j.bmc.2011.08.015]

Source